Ionis Pharmaceuticals Inc. – Q3 2026 Financial Performance and Guidance Update
The biotechnology company Ionis Pharmaceuticals Inc. (NASDAQ: IONS) reported its third‑quarter earnings on November 10, 2026. Revenue rose 55 % to $243 million, exceeding analysts’ estimates. The company also posted a net loss of $110 million for the quarter, reflecting ongoing investment in research and development and higher operating expenses.
Despite the revenue beat, Ionis’s stock fell sharply after the earnings release. Shares traded as low as $28.00 during the session, ending the day at $31.00—a decline of 21.36 % from the Friday close of $39.42. The decline was attributed primarily to a significant reduction in the guidance for the key product Tryngolza (Olezarsen), a triglyceride‑lowering therapy that the company had previously projected to generate $100–$110 million in 2026 sales. On November 9, Ionis lowered the 2026 sales forecast for Tryngolza to roughly $50 million, a cut of about 50 %. This revision was communicated to investors in a July notice that the product was “on track” for the higher range, and the subsequent downgrade was described as “on track” but “lowered” in the November 9 PR‑Newswire release.
The guidance cut has led to a series of analyst adjustments. TD Cowen, RBC, Wells Fargo, Raymond James, Deutsche Bank, and other research houses all reduced their price targets for Ionis, citing the slower launch and reduced revenue expectations for Tryngolza. Deutsche Bank downgraded its rating to “hold (buy)”, noting new challenges in the U.S. market for the specialist drug. In addition, a “soci‑b” (SOBI) note from Stockholm’s DirectNews reported Deutsche Bank’s concerns regarding the partnership with Ionis for the Tryngolza launch.
Ionis also announced a broader 2026 revenue outlook of $875–$900 million in a Seeking Alpha article on November 9, but this figure excludes the reduced Tryngolza contribution. The company reiterated its commitment to developing RNA‑targeted therapies and emphasized that the company’s long‑term strategy remains focused on addressing unmet medical needs.
Market reaction to the news was swift. The shares entered a 52‑week low on Monday, November 13, 2026, trading near $27.75, the lowest level since July 7 when the 52‑week high was $86.74. The close price on November 9 was $28.19, reflecting a substantial decline from the 5‑year peak of $86.74.
In summary, Ionis Pharmaceuticals achieved a strong Q3 revenue performance but was offset by a significant net loss and a major downward revision to its flagship product’s sales outlook. Analyst coverage has become more bearish, and the stock has experienced a notable decline in price, falling to 52‑week lows following the guidance revision.
